This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants. The study consists of a screening period, a dosing period (Cycles 1, 2, 3, and 4), and a follow-up period. Screening must occur within 14 days prior to the first dose of study drug. Enrolled participants will be randomly assigned to one of 6 dosing sequences in the ratio of 1:1:1:1:1:1 to complete Cycles 1-3 dosing to evaluate the effect of different types of food on the PK of HMPL-760, and then to receive rabeprazole and HMPL-760 in Cycle 4 to assess the effect of PPI on the PK of HMPL-760 (see dosing sequence table for details).

Inclusion Criteria:

1. Participants are fully aware of this study and voluntarily sign the ICF.
2. Male or female aged 18 to 45 years old (inclusive).
3. Participant's body mass index (BMI) at screening: 18 kg/m2 < BMI ≤ 29.9 kg/m2 and weight ≥ 50 kg for males and ≥ 45 kg for females.
4. Participant is willing and able to comply with the protocol in all aspects.

Exclusion Criteria:

1. Known history of any gastrointestinal surgery or any condition that could affect drug absorption (e.g., cholecystectomy, achlorhydria, peptic ulcer disease, gastric/intestinal surgery or history of resection; prior appendectomy or hernia repair is allowed).
2. Clinically significant disease within 8 weeks prior to the first dose or clinically significant infection within 4 weeks prior to the first dose.
3. Clinically significant abnormal findings in physical examination, vital signs, or laboratory tests at screening.
4. Systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg at screening.
5. Participants who smoked over 10 cigarettes daily within 3 months before screening.